PBS listing changes effective 1 May 2025
21 May 2025
Update
Services Australia have announced recent changes to Pharmaceutical Benefits Scheme (PBS) effective from 1 May 2025. This includes listings relevant to psychiatric practice reprinted below:
- Schizophrenia
Aripiprazole (720 mg/2.4 mL modified release injection, 2.4mL syringe; 960 mg/3.2 mL modified release injection, 3.2mL syringe; (Abilify Asimtufii®) is now listed on the PBS for the treatment of schizophrenia. Prescriptions for treatment are Authority required (STREAMLINED). - Treatment resistant major depression
Esketamine (28 mg/2 actuations nasal spray, 2 actuations; 28 mg/2 actuations nasal spray, 2 x 2 actuations; 28 mg/2 actuations nasal spray, 3 x 2 actuations) (Spravato®) is now listed on the PBS for the treatment of treatment resistant major depression. Authority applications for initial (induction), grandfather and continuing (non-induction) treatments can be made either in real-time using the Online PBS Authorities system of by telephone.
Further details about these and other listing changes are available via the PBS website.
More news & views
30 October 2025
From the President October 2025
Another month has come to a close and another edition of Psyche has hit your inbox. Today, before yo...
21 October 2025
RANZCP South Australia Branch hosted its 66th annual Barton Pope Lecture
In recognition of Mental Health Month, the RANZCP South Australia Branch hosted its 66th annual Bart...
21 October 2025
2025 Psychiatry Interest Forum facilitated networking activity
This year’s event was held at the University of Tasmania and University of New Castle/New England an...